RESUMO
At present there is a lack of well-validated surveys used to measure quality of life in patients with malignant brain tumors and their caregivers. The main objective of this pilot study was to validate the National Institutes of Health Patient-Reported Outcomes Measurement Information System (NIH PROMIS) survey for use as a quality-of-life measure in this population. This article presents the rationale for using the NIH PROMIS instrument as a quality-of-life measure for patients with malignant brain tumors and their caregivers.
Assuntos
Neoplasias Encefálicas/psicologia , Cuidadores/psicologia , Processo de Enfermagem , Qualidade de Vida , Inquéritos e Questionários , Adulto , Idoso , Astrocitoma/enfermagem , Astrocitoma/patologia , Astrocitoma/psicologia , Neoplasias Encefálicas/enfermagem , Neoplasias Encefálicas/patologia , Feminino , Glioblastoma/enfermagem , Glioblastoma/patologia , Glioblastoma/psicologia , Humanos , Sistemas de Informação , Masculino , Pessoa de Meia-Idade , National Institutes of Health (U.S.) , Metástase Neoplásica , Projetos Piloto , Reprodutibilidade dos Testes , Estados UnidosRESUMO
Peripheral intravenous (IV) access provides a means to administer medications, IV fluids, and blood products and allows for the sampling of blood for analysis. The traditional approach to obtaining peripheral IV access relies on vessel visualization in the arm and/or palpation of the blood vessel beneath the skin. However, the general population is aging, obesity is commonplace, and IV drug abuse is widespread, making peripheral IV access difficult. Use of ultrasound-guided peripheral IV access fills a practice gap in safe patient care between traditional peripheral IV access methods of vein visualization and/or palpation and ultrasound-guided central venous access.